Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $152.00 at SVB Leerink

Intellia Therapeutics (NASDAQ:NTLAGet Rating) had its price objective lowered by SVB Leerink from $155.00 to $152.00 in a research report released on Friday, MarketBeat Ratings reports. The brokerage currently has an outperform rating on the stock.

A number of other brokerages have also issued reports on NTLA. The Goldman Sachs Group reduced their target price on Intellia Therapeutics from $206.00 to $180.00 and set a buy rating for the company in a research note on Tuesday, May 24th. Credit Suisse Group initiated coverage on Intellia Therapeutics in a research note on Thursday, April 28th. They issued an outperform rating and a $100.00 target price for the company. BMO Capital Markets initiated coverage on Intellia Therapeutics in a research note on Thursday, June 16th. They issued a market perform rating and a $54.00 target price for the company. Bank of America initiated coverage on Intellia Therapeutics in a research note on Thursday, June 16th. They issued a buy rating and a $70.00 target price for the company. Finally, JMP Securities reduced their target price on Intellia Therapeutics from $165.00 to $110.00 in a research note on Monday, May 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus target price of $131.06.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $63.32 on Friday. The stock’s 50-day simple moving average is $55.42 and its 200 day simple moving average is $64.22. The stock has a market capitalization of $4.80 billion, a price-to-earnings ratio of -11.84 and a beta of 2.00. Intellia Therapeutics has a 52-week low of $37.08 and a 52-week high of $180.59.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.03). Intellia Therapeutics had a negative return on equity of 38.74% and a negative net margin of 883.17%. The company had revenue of $14.00 million for the quarter, compared to analysts’ expectations of $9.50 million. During the same period last year, the company posted ($1.01) EPS. The business’s revenue for the quarter was up 115.4% on a year-over-year basis. On average, research analysts forecast that Intellia Therapeutics will post -5.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Intellia Therapeutics

Several institutional investors have recently bought and sold shares of NTLA. ARK Investment Management LLC boosted its holdings in Intellia Therapeutics by 13.4% in the 1st quarter. ARK Investment Management LLC now owns 8,981,029 shares of the company’s stock worth $652,651,000 after buying an additional 1,064,147 shares during the last quarter. Viking Global Investors LP boosted its holdings in Intellia Therapeutics by 56.3% in the 1st quarter. Viking Global Investors LP now owns 2,468,760 shares of the company’s stock worth $179,405,000 after buying an additional 889,224 shares during the last quarter. State Street Corp boosted its holdings in Intellia Therapeutics by 30.2% in the 1st quarter. State Street Corp now owns 2,397,527 shares of the company’s stock worth $174,228,000 after buying an additional 556,076 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Intellia Therapeutics by 14.7% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,753,903 shares of the company’s stock worth $325,621,000 after buying an additional 353,970 shares during the last quarter. Finally, Nikko Asset Management Americas Inc. lifted its stake in Intellia Therapeutics by 14.7% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 2,753,903 shares of the company’s stock worth $327,714,000 after purchasing an additional 353,970 shares in the last quarter. 85.89% of the stock is currently owned by institutional investors and hedge funds.

About Intellia Therapeutics

(Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Featured Stories

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.